Business Wire

QUECTEL-WIRELESS

14.11.2022 09:01:38 CET | Business Wire | Press release

Share
Quectel Announces Extended Wi-Fi 6 and Wi-Fi 6E Module Portfolio to Address Smart Home and Commercial Applications

Quectel Wireless Solutions, a global IoT solutions provider, today announces its expanded Wi-Fi module portfolio with the launch of the FC6xE series of Wi-Fi/Bluetooth modules, based on Qualcomm’s QCA206x Wi-Fi 6E chip. Designed to deliver faster, more secure, and more robust Wi-Fi experiences than ever before, the FC6xE also features Bluetooth audio functionality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221113005138/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel announces extended Wi-Fi 6/6E module portfolio to address home and commercial environments (Photo: Business Wire)

Supporting 2 × 2 MIMO and DBS, the FC6xE family provides a maximum data rate up to 3000 Mbps. With a compact and unified form factor of 19.9 mm × 18.0 mm × 2.1 mm, the FC6xE modules are the optimal Wi-Fi/Bluetooth solution for size-sensitive applications and can help customers reduce product size and optimize application design cost.

“Targeting the nascent Wi-Fi 6/6E market, the FC62E, FC64E, FC65E and FC66E all offer superior Wi-Fi 6/6E performance,” commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "When used in combination with Quectel 5G modules, they also deliver best-in-class 5G functionality, guaranteeing ultra-reliable connections for a wide range of multi-user scenarios including smart homes, shopping malls, schools and factories.”

The modules join an already extensive range of Wi-Fi/Bluetooth modules delivering functionality across Wi-Fi 4, Wi-Fi 5, Wi-Fi 6, and Wi-Fi 6E.

RF Wi-Fi/Bluetooth modules

  • FC20/21 - typically used in connecting with different Linux/Android application processors, the compact form factor, low power consumption, extended temperature range and stable SDIO interface allow this module to serve a wide range of IoT applications including consumer, safety, industrial, mobile hotspots and healthcare.
  • FC80A - a high-performance Wi-Fi 5 module, supporting 2.4GHz and 5GHz RSDB (Real simultaneous dual band) and Bluetooth 5.1, the FC80A can meet the Wi-Fi & Bluetooth application design requirements expected across consumer fields including set top boxes and VR.
  • FC909A - with a reliable SDIO 2.0 interface enabling WLAN capability, the FC909A also provides BT functions with low power consumption, making it ideal for mobile devices requiring battery powered and compact size.

MCU Wi-Fi/Bluetooth Modules

  • FC41D - Based on a standalone Wi-Fi & Bluetooth chip, the FC41D can offer diversified applications for customers. Combined with its ultra-compact size, low power consumption, ultra-wide temperature range and high reliability, FC41D can meet the requirements of low flow control and data acquisition applications such as smart homes and industrial control.

The hosted range of Wi-Fi/Bluetooth modules are ideal for both home and commercial applications including set top boxes, smart TVs, and smart speakers in the home and POS, scanner, and printer applications in a business environment. The hosted range is also appropriate for a wide range of telematics applications. The MCU Wi-Fi/Bluetooth module is typically used as a connectivity link between IoT devices and public or private cloud.

Complementing the FC6xE modules are a range of antennas across the 2.4Ghz and 6Ghz spectrum including the YF0026AA FPC, YF0027AA FPC, YF0023AA FR4 and YEWT004AA while additional antennas can support 5Ghz spectrum.

For more information on the Quectel range of Wi-Fi/Bluetooth modules, head over to our website: https://www.quectel.com/wifi-iot-modules

For more information on Quectel antennas: https://www.quectel.com/product-category/antennas

Download our Wi-Fi 6 white paper: https://www.quectel.com/library/wifi-6-white-paper

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth® modules, antennas and IoT connectivity. With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221113005138/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye